Scarica l'app Stockscreener
95.31
2.38%
-2.32
Dopo l'orario di chiusura:
96.82
1.51
+1.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$97.63
Aprire:
$97.44
Volume 24 ore:
1.64M
Relative Volume:
1.06
Capitalizzazione di mercato:
$19.04B
Reddito:
$5.36B
Utile/perdita netta:
$1.43B
Rapporto P/E:
13.48
EPS:
7.0718
Flusso di cassa netto:
$1.42B
1 W Prestazione:
-3.30%
1M Prestazione:
-1.84%
6M Prestazione:
-8.49%
1 anno Prestazione:
+51.86%
Intervallo 1D:
$94.31
$97.70
Intervallo di 1 settimana:
$94.31
$103.01
Portata 52W:
$62.73
$112.29
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
95.31 | 19.50B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies - AD HOC NEWS
Dodge & Cox holds 12.25M Incyte shares (NASDAQ: INCY), a 6.2% stake - Stock Titan
FDA Approves Once-Daily Jakafi XR for Blood Disorders - MyChesCo
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Associa - PharmiWeb.com
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress - BioSpace
Incyte to Present Pipeline Strategy at May Investor Conferences - MyChesCo
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24 - Insider Monkey
Incyte Appoints Suketu Upadhyay as Chief Financial Officer - MyChesCo
Incyte Reports Q1 Revenue Growth as Pipeline Advances - MyChesCo
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Incyte Corp. Receives Favorable Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)? - Yahoo Finance
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis - BioSpace
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
Incyte presents 24-week data for ruxolitinib cream in atopic dermatitis - Investing.com
Incyte eczema cream held disease control through 24 weeks - Stock Titan
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 - BioSpace
Incyte (NASDAQ: INCY) grants CFO RSUs, options and performance shares - Stock Titan
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Here's Why Incyte (INCY) is a Strong Growth Stock - Yahoo Finance
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Incyte Corp. Receives Positive Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Incyte (INCY) Receives FDA Orphan Designation for Pancreatic Can - GuruFocus
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $135 - Moomoo
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] - Quantisnow
Australia approves new therapy for transplant patients with chronic GVHD - Stock Titan
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings - Insider Monkey
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extende - The National Law Review
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte (INCY) Gains FDA Approval for Jakafi XR Treatment - GuruFocus
FDA approves Incyte’s once-daily Jakafi XR formulation - Investing.com
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Quantisnow
Incyte: Strong Business, But Risks Remain (NASDAQ:INCY) - Seeking Alpha
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
INCY SWOT Analysis: Strong Financial Performance Revealed in 10-Q Filing - GuruFocus
Vanguard Capital Management (INCY) discloses 6.32% ownership in Incyte Corp - Stock Titan
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):